Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

Sullivan RJ, Tschernia NP, Friedman CF, Herrera M, Sonpavde GP, He K, Italiano A, Marabelle A, Roulleaux-Dugage M, Danlos FX, Cabanas EG, Hernando-Calvo A, Pedregal M, Parikh A, Iyer G, Zakari A, Wherry EJ, Schlom J, Donahue RN, McCue S, Cross S, Srinivasan K, Benincosa L, Katragadda M, Shun Z, Chin K, Su Z, Liu K, Siu LL, Gulley JL

Open source

DOI: 10.1038/s41591-026-04711-0
Published: 2026 Oct 23
Container: Nature medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04711-0,
  title = {Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.},
  author = {Sullivan RJ and Tschernia NP and Friedman CF and Herrera M and Sonpavde GP and He K and Italiano A and Marabelle A and Roulleaux-Dugage M and Danlos FX and Cabanas EG and Hernando-Calvo A and Pedregal M and Parikh A and Iyer G and Zakari A and Wherry EJ and Schlom J and Donahue RN and McCue S and Cross S and Srinivasan K and Benincosa L and Katragadda M and Shun Z and Chin K and Su Z and Liu K and Siu LL and Gulley JL},
  year = {2026},
  journal = {Nature medicine},
  doi = {10.1038/s41591-026-04711-0},
  url = {https://doi.org/10.1038/s41591-026-04711-0}
}

RIS

TY  - JOUR
TI  - Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.
AU  - Sullivan RJ
AU  - Tschernia NP
AU  - Friedman CF
AU  - Herrera M
AU  - Sonpavde GP
AU  - He K
AU  - Italiano A
AU  - Marabelle A
AU  - Roulleaux-Dugage M
AU  - Danlos FX
AU  - Cabanas EG
AU  - Hernando-Calvo A
AU  - Pedregal M
AU  - Parikh A
AU  - Iyer G
AU  - Zakari A
AU  - Wherry EJ
AU  - Schlom J
AU  - Donahue RN
AU  - McCue S
AU  - Cross S
AU  - Srinivasan K
AU  - Benincosa L
AU  - Katragadda M
AU  - Shun Z
AU  - Chin K
AU  - Su Z
AU  - Liu K
AU  - Siu LL
AU  - Gulley JL
PY  - 2026
JO  - Nature medicine
DO  - 10.1038/s41591-026-04711-0
UR  - https://doi.org/10.1038/s41591-026-04711-0
ER  -

APA

RJ, S., NP, T., CF, F., M, H., GP, S., K, H., A, I., A, M., M, R., FX, D., EG, C., A, H., M, P., A, P., G, I., A, Z., EJ, W., J, S., RN, D., S, M., S, C., K, S., L, B., M, K., Z, S., K, C., Z, S., K, L., LL, S., & JL, G. (2026). Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04711-0

Source records

pubmed · retrieved 2026-11-10T12:15:33.926Z